Earnings Beat: Micro Systemation AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Investors in Micro Systemation AB (publ) (STO:MSAB B) had a good week, as its shares rose 2.2% to close at kr84.00 following the release of its quarterly results. Although revenues of kr123m were in line with analyst expectations, Micro Systemation surprised on the earnings front, with an unexpected (statutory) profit of kr0.51 per share a nice improvement on the losses that the analystsforecast. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

earnings-and-revenue-growth
OM:MSAB B Earnings and Revenue Growth July 19th 2026

Taking into account the latest results, the consensus forecast from Micro Systemation's two analysts is for revenues of kr540.5m in 2026. This reflects an okay 5.8% improvement in revenue compared to the last 12 months. Statutory earnings per share are expected to sink 11% to kr3.37 in the same period. Before this earnings report, the analysts had been forecasting revenues of kr540.0m and earnings per share (EPS) of kr2.91 in 2026. There was no real change to the revenue estimates, but the analysts do seem more bullish on earnings, given the decent improvement in earnings per share expectations following these results.

View our latest analysis for Micro Systemation

The analysts have been lifting their price targets on the back of the earnings upgrade, with the consensus price target rising 12% to kr96.00.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The analysts are definitely expecting Micro Systemation's growth to accelerate, with the forecast 12% annualised growth to the end of 2026 ranking favourably alongside historical growth of 8.3% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 7.1% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Micro Systemation to grow faster than the wider industry.

Advertisement

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Micro Systemation following these results. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have analyst estimates for Micro Systemation going out as far as 2028, and you can see them free on our platform here.

That said, it's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Micro Systemation , and understanding this should be part of your investment process.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OM:MSAB B

Micro Systemation

Provides forensic technology for mobile device examination and analysis in Sweden and internationally.

Outstanding track record with flawless balance sheet.

Advertisement

Weekly Picks

DA
davidlsander
NAUF.F logo
davidlsander on Nevgold ·

The U.S. Government Is Desperate for This Metal. This Tiny Miner Has It -- Its Closest Peer Is Already Worth Double.

Fair Value:US$2.1946.6% undervalued
35 users have followed this narrative
0 users have commented on this narrative
3 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.0% undervalued
61 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative
JD
CELH logo
JD009 on Celsius Holdings ·

From $5M to $2B: Why the 2024 Crash Was the Best Buying Opportunity in Consumer Stocks

Fair Value:US$55.4347.7% undervalued
22 users have followed this narrative
1 users have commented on this narrative
8 users have liked this narrative
WA
ACN logo
Wavefarer on Accenture ·

High-quality global services company facing an AI-driven valuation reset.

Fair Value:US$30152.3% undervalued
16 users have followed this narrative
1 users have commented on this narrative
6 users have liked this narrative

Updated Narratives

AN
AnimalDoctorKwon
RARE logo
AnimalDoctorKwon on Ultragenyx Pharmaceutical ·

burns cash despite four approved drugs, trapped by structural inefficiencies and gene-therapy scaling hurdles that thin safety margins.

Fair Value:US$2612.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
BBIO logo
AnimalDoctorKwon on BridgeBio Pharma ·

Faces a brutal commercial dogfight against Pfizer’s entrenched monopoly and Alnylam’s silencers, compressing its safety margins

Fair Value:US$25225.5% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
AN
AnimalDoctorKwon
ROIV logo
AnimalDoctorKwon on Roivant Sciences ·

overprices legal wins and pipeline, ignoring fierce anti-FcRn competition, cash redeployment drag, and holding discounts.

Fair Value:US$10245.1% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

IN
Investingwilly
MA logo
Investingwilly on Mastercard ·

Mastercard: The Best Dividend Stock You're Ignoring

Fair Value:US$75027.5% undervalued
96 users have followed this narrative
1 users have commented on this narrative
9 users have liked this narrative
BL
BlackGoat
CBRS logo
BlackGoat on Cerebras Systems ·

The Wafer Giant Threatening NVIDIA's GPU Hegemony

Fair Value:US$415.5458.4% undervalued
63 users have followed this narrative
3 users have commented on this narrative
11 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.0% undervalued
61 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative